An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer
- Conditions
- Recurrent Bladder Cancer
- Registration Number
- NCT03801278
- Lead Sponsor
- Five Prime Therapeutics, Inc.
- Brief Summary
This is an open-label, expanded access protocol to continue administration of bemarituzumab (FPA144) in a single patient with recurrent bladder cancer
- Detailed Description
This protocol is intended to provide access to bemarituzumab (FPA144 an investigational agent) to a single patient with recurrent bladder cancer who had a response to study drug on FPA144-001. That study is closing and this expanded access protocol allows this single patient to continue receiving this agent.
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- Male
- Target Recruitment
- Not specified
Inclusion Criteria
- Understand and sign an Institutional Review Board-approved informed consent form prior to receiving bemarituzumab
- Previously enrolled on the FPA144-001 study, received bemarituzumab and obtained clinical benefit from the investigational product (IP) administration
Read More
Exclusion Criteria
- Pregnancy and lactation
Read More
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method